Regulative mechanisms of mammalian target of rapamycin signaling pathway in glomerular hypertrophy in diabetic nephropathy and interventional effects of Chinese herbal medicine

2015 ◽  
Keyword(s):  
Diabetic Nephropathy ◽  
Herbal Medicine ◽  
Signaling Pathway ◽  
Chinese Herbal Medicine ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Glomerular Hypertrophy ◽  
Chinese Herbal

scholarly journals Efficacy and safety of acupuncture combined with Chinese Herbal Medicine for diabetic nephropathy

Medicine ◽  
2021 ◽  
Vol 100 (35) ◽  
pp. e27087
Author(s):  
Ziyang Yu ◽  
Wenfeng Zhang ◽  
Borui Li ◽  
Pengjie Bao ◽  
Fengyang Wang ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Efficacy And Safety ◽  
Chinese Herbal

scholarly journals The Effect of Chinese Herbal Medicine on Albuminuria Levels in Patients with Diabetic Nephropathy: A Systematic Review and Meta-Analysis

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Ya Xiao ◽  
Yanyan Liu ◽  
Keqiang Yu ◽  
Lin Zhou ◽  
Jianlu Bi ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Large Scale ◽  
Angiotensin Receptor Blockers ◽  
Urinary Albumin ◽  
Cochrane Library ◽  
Creatinine Ratio ◽  
Serious Adverse Events ◽  
Chinese Herbal

To evaluate the effect of Chinese herbal medicine (CHM) on albuminuria levels in patients with diabetic nephropathy (DN), we performed comprehensive searches on Medline database, Cochrane Library, CNKI database, CBM database, Wanfang database, and VIP database up to December 2012. A total of 29 trials including 2440 participants with DN met the selection criteria. CHM was tested to be more effective in reducing urinary albumin excretion rate (UAER) (MD −82.95 μg/min, [−138.64, −27.26]) and proteinuria (MD −565.99 mg/24 h, [−892.41, −239.57]) compared with placebo. CHM had a greater beneficial effect on reduction of UAER (MD −13.41 μg/min, [−20.63, −6.19]) and proteinuria (MD −87.48 mg/24 h, [−142.90, −32.06]) compared with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). Combination therapy with CHM and ACEI/ARB showed significant improvement in UAER (MD −28.18 μg/min, [−44.4, −11.97]), urinary albumin-creatinine ratio (MD −347.00, [−410.61, −283.39]), protein-creatinine ratio (MD −2.49, [−4.02, −0.96]), and proteinuria (MD −26.60 mg/24 h, [−26.73, −26.47]) compared with ACEI/ARB alone. No serious adverse events were reported. CHM seems to be an effective and safe therapy option to treat proteinuric patients with DN, suggesting that further study of CHM in the treatment of DN is warranted in rigorously designed, multicentre, large-scale trials with higher quality worldwide.

Sign in / Sign up

Export Citation Format

Share Document